ACTRN12610000733077已完成1 期
A Single Dose, Dose Escalating, Phase I Clinical Trial to Determine the Safety of a Single Dose of PAT-SM6 Monoclonal Antibody in Patients with Recurrent In-Transit Cutaneous Melanoma
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1.The patient has recurrent in-transit cutaneous melanoma based on diagnosis by cytology or histology. The patient may or may not have asymptomatic distant metastatic disease limited to Stage M1a.
- •2.The patient is willing and able to provide a pre- and post-treatment tumour biopsy.
- •3.The patient has an Eastern Cooperative Oncology Group (ECOG) performance status Grade of 0, 1 or 2 at study entry.
- •4.The patient has provided written informed consent.
- •5.The patient is age 18 years or older.
- •6.The patient has a life expectancy of > 3 months.
- •7.The patient has adequate hematologic function, as defined by: - an absolute neutrophil count >= 1500/mm3 - a platelet count >= 100,000/mm3
- •8. The patient has a haemoglobin level >9 g/dL.
- •9.The patient has adequate hepatic function, as defined by: - a total bilirubin level <= the upper limit of normal (ULN) unless due to congenital Gilbert’s syndrome - aspartate transaminase (AST) and alanine transaminase (ALT) levels <= 2.5 x the ULN
- •10.The patient has adequate renal function, with calculated creatinine clearance (using Cockcroft Gault formula) of >50 mL/min and 0 to 1+ proteinuria.
- •11.The patient uses effective contraception (per the institutional standard), if procreative potential exists.
- •12.The patient has adequately recovered from any recent therapy, including surgery, chemotherapy, and radiation therapy.
- •13.The patient is accessible for treatment and follow-up at the participating centre.
排除标准
- •1.The patient has metastatic disease at Stage M1b (lung metastases with normal LDH of <=ULN) or M1c (other distant metastases or any distant metastases with elevated LDH of >ULN). 2. The patient has received chemotherapy or therapeutic radiotherapy within 28 days prior to the first dose of study medication or has ongoing side effects >= Common Terminology Criteria for Adverse Events (CTCAE) (Version 4.0) Grade 2 due to agents administered more than 28 days earlier. 3.Immunosuppressive therapy including corticosteroids within four weeks of screening; 4. The patient has uncontrolled intercurrent illness including, but not limited to: - ongoing or active infection requiring parenteral antibiotics, - symptomatic congestive heart failure (class III or IV of the New York Heart Association classification for heart disease), - unstable angina pectoris, angioplasty, stenting, or myocardial infarction six months prior to the first dose of study medication, - uncontrolled hypertension (systolic blood pressure >160 mmHg, diastolic blood pressure >100 mmHg, found on two consecutive measurements separated by a one week period despite adequate medical support), - clinically significant cardiac arrhythmia including but not limited to: multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia that is symptomatic or requires treatment, CTCAE, Version 4.0, Grade 3, or asymptomatic sustained ventricular tachycardia, - uncontrolled diabetes, - psychiatric illness/social situations that would compromise patient safety or limit compliance with study requirements, 5.The patient has known human immunodeficiency virus positivity. 6.The patient has had a major surgical procedure or a significant traumatic injury within 28 days prior to treatment. 7.The patient is currently or has recently used (within 28 days prior to) a thrombolytic agent. 8.The patient is currently using full-dose warfarin (an exception is low-dose warfarin to maintain patency of pre-existing, permanent, indwelling intravenous catheters; for patients receiving warfarin, the international normalised ratio [INR] should be <1.5). A patient requiring heparin is excluded. A patient receiving antiplatelet agents such as non-steroidal anti-inflammatory drugs including aspirin, clopidogrel and dipyramidole is excluded. 9.Known hemorrhagic diathesis or active bleeding disorder. 10.The patient has any condition, which in the Investigator’s opinion, puts the patient at significant risk, could confound study results, or may interfere with the patient’s participation in the study. 11.The patient has received an Investigational Product within 30 days prior to dosing, or five half-lives of the drug whichever is longer. 12.The patient has a QTc interval of greater than 450 ms (males) and 470 ms (females).
研究者
相似试验
尚未招募
1 期
SAD, Phase I Trial to Assess Safety, Tolerability and PK Profile of MSP008-22in Patients With Advanced Solid TumoursCTRI/2022/06/043504Godavari Biorefineries Limited
已完成
不适用
A single ascending dose escalation clinical trial to investigate safety and pharmacokinetics of VVZ-149 injection in healthy older male volunteersDiseases of the nervous systemKCT0001345Vivozon24
撤回
不适用
A Phase I, exploratory, intra-patient dose escalation study to investigate the preliminary safety, pharmacokinetics, and anti-tumor activity of pasireotide (SOM230) s.c. followed by pasireotide LAR in patients with metastatic melanoma or metastatic Merkel cell carcinomaSkin cancerMelanomaNL-OMON40385ovartis4
招募中
不适用
A Phase I clinical study to evaluate the safety and efficacy of allogenic adipose-derived stem cells in the patients with Crohn's fiatula.Symptoms, signs and abnormal clinical and laboratory findings, NECKCT0000188Anterogen6
未知
1 期
A Phase 1, Open-label, Single-arm, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-573, a Fully Human Monoclonal Antibody Directed Against Insulin-like Growth Factors 1 and 2, in Japanese Subjects With Advanced Solid Tumours Refractory to Standard Therapy or for Which No Standard Therapy ExistsJPRN-jRCT2080221544AstraZeneca